

1 Proteomic and Metabolomic Investigation of COVID-19 2 Patients with Elevated Serum Lactate Dehydrogenase

3 Haixi Yan^{1#}, Xiao Liang^{2,3,4#}, Juping Du^{1,#}, Zebao He^{1,#}, Yu Wang⁵, Mengge Lyu^{2,3,4},
4 Liang Yue^{2,3,4}, Fangfei Zhang^{2,3,4}, Zhangzhi Xue^{2,3,4}, Luang Xu^{2,3,4}, Guan Ruan⁶, Jun
5 Li¹, Hongguo Zhu¹, Jiaqin Xu¹, Shiyong Chen¹, Chao Zhang¹, Dongqing Lv¹,
6 Zongmei Lin¹, Bo Shen¹, Yi Zhu^{2,3,4†}, Biyun Qian^{5,†}, Haixiao Chen^{1,†}, Tiannan
7 Guo^{2,3,4†}

8 ¹ Taizhou Hospital of Zhejiang Province affiliated to Wenzhou Medical University,
9 150 Ximen Street, Linhai 317000, Zhejiang Province, China

10 ² Key Laboratory of Structural Biology of Zhejiang Province, School of Life
11 Sciences, Westlake University, 18 Shilongshan Road, Hangzhou 310024, Zhejiang
12 Province, China

13 ³ Center for Infectious Disease Research, Westlake Laboratory of Life Sciences and
14 Biomedicine, Hangzhou 310024, China

15 ⁴ Institute of Basic Medical Sciences, Westlake Institute for Advanced Study, 18
16 Shilongshan Road, Hangzhou 310024, Zhejiang Province, China

17 ⁵ Hongqiao International Institute of Medicine, Shanghai Tongren Hospital and
18 Faculty of Public Health, Shanghai Jiao Tong University School of Medicine,
19 Shanghai 200025, China

20 ⁶ Westlake Omics (Hangzhou) Biotechnology Co., Ltd. No.1, Yunmeng Road, Cloud
21 Town, Xihu District, Hangzhou, Zhejiang Province, China

22
23 # These authors contributed equally to this study.

24 † Correspondence and requests for materials should be addressed to Z.Y.
25 (zhuyi@westlake.edu.cn), B.Q. (qianbiyun@sjtu.edu.cn), H.C.
26 (chenhx@enzemed.com), and T.G. (guotiannan@westlake.edu.cn).

27
28 **Keywords:** COVID-19; lactate dehydrogenase; proteomics; metabolomics;
29 biomarker; prognosis
30

31 **Abstract**

32 Serum lactate dehydrogenase (LDH) has been established as a prognostic indicator
33 given its differential expression in COVID-19 patients. However, the molecular
34 mechanisms underneath remain poorly understood. In this study, 144 COVID-19
35 patients were enrolled to monitor the clinical and laboratory parameters over three
36 weeks. Serum lactate dehydrogenase (LDH) was shown elevated in the COVID-19
37 patients on admission and declined throughout disease course, and its ability to
38 classify patient severity outperformed other biochemical indicators. A threshold of
39 247 U/L serum LDH on admission was determined for severity prognosis. Next, we
40 classified a subset of 14 patients into high- and low-risk groups based on serum LDH
41 expression and compared their quantitative serum proteomic and metabolomic
42 differences. The results found COVID-19 patients with high serum LDH exhibited
43 differentially expressed blood coagulation and immune responses including acute
44 inflammatory responses, platelet degranulation, complement cascade, as well as
45 multiple different metabolic responses including lipid metabolism, protein
46 ubiquitination and pyruvate fermentation. Specifically, activation of hypoxia
47 responses was highlighted in patients with high LDH expressions. Taken together, our
48 data showed that serum LDH levels are associated COVID-19 severity, and that
49 elevated serum LDH might be consequences of hypoxia and tissue injuries induced by
50 inflammation.

51

52 INTRODUCTION

53 COVID-19 is an ongoing global pandemic caused by severe acute respiratory
54 syndrome coronavirus 2 (SARS-CoV-2). A high viral transmission rate and the lack of
55 effective therapy contributed to more than 83 million infected cases as of time January
56 3rd, 2021 [1].

57 To better diagnose COVID-19 and monitor the disease progress, multiple molecules
58 have been proposed as prognostic indicators [2]. Lactate dehydrogenase (LDH) is an
59 intracellular enzyme, catalyzing pyruvate fermentation and facilitating glycolysis.
60 LDH is released into the blood after cell death and has been reported to increase in a
61 variety of diseases including Severe acute respiratory syndrome (SARS) [3], diabetes
62 [4], and cancers [5]. Serum LDH levels in COVID-19 patients are over-expressed [2],
63 especially in severe and critical patients [6-9]. They decrease throughout disease course
64 [7,10], in correlation with viral mRNA clearance [7]. Related studies have shown that
65 serum LDH is well correlated with respiratory failure [11], lung injury, disease severity
66 [12] and mortality [13] in COVID-19 patients.

67 However, the molecular mechanisms underlying the LDH's association with the
68 COVID-19 disease progression remains poorly understood. Most studies attribute
69 serum LDH elevation to its release from somatic tissue and organ damage caused by
70 either viral attack [12] or inflammation [10]. These clinical assumptions lack molecular
71 evidence, potentially leading to biased assessments. Moreover, these explanations
72 failed to consider the metabolic role of LDH to balance excess lactate during hypoxia.
73 Here we have systematically explored the proteome and metabolome of sera from
74 COVID-19 patients with low and high serum LDH, and identified the specific host
75 responses, which shed light on the pathogenesis and convalesce of COVID-19.

76

77 MATERIALS AND METHODS

78 *Patient Information*

79 We collected and curated the electronic medical records of patient information in
80 Taizhou Hospital of Zhejiang Province, between January 17 and February 20, 2020.
81 212 patients met the criteria of suspected COVID-19, of which 145 patients were
82 confirmed as COVID-19, based on the Government's Diagnosis and Treatment
83 Guideline (5th version) [14]. 144 patients COVID-19 patients were included in this
84 study after excluding one patient who had incomplete laboratory data. According to
85 the admission period, we grouped them into two cohorts. Patients admitted to Taizhou
86 Public Health Medical Center, Taizhou Hospital between January 17 and February 4,
87 2020 were included in the cohort 1 (n = 115). The cohort 2 (n = 29) contained
88 COVID-19 patients admitted from February 4 to February 20, 2020. The end of the
89 follow-up date was March 1, 2020. Disease severity was accessed according to the
90 abovementioned guideline. We classified COVID-19 patients into two groups (severe
91 and non-severe): the severe group included severe and critical patients, and the non-
92 severe group included mild and typical patients. Briefly, those who had shortness of
93 breath with respiratory rate ≥ 30 breaths/min, a ratio of arterial blood oxygen partial
94 pressure to oxygen concentration ≤ 300 mmHg or saturation of oxygen $\leq 93\%$ when
95 resting were defined as severe patients. The other COVID-19 patients were grouped
96 as non-severe patients. 125 healthy individuals were enrolled as controls.
97 This study was conducted in accordance with the Helsinki Declaration and was
98 approved by the institutional medical ethics review boards of Taizhou Hospital of
99 Zhejiang Province and Westlake University (Approval ID: 20210119GTN001).

100 **Laboratory tests**

101 Samples were taken throughout disease course from patient admission to discharge.
102 More details are described in Supplementary Table 1. For laboratory tests, 404 serial
103 blood samples from 144 patients were collected and centrifuged at 1500 g for 10 min
104 at room temperature.

105 For serum of COVID-19 patients, seven biochemical indicators were tested, namely
106 lactate dehydrogenase (LDH), aspartate aminotransferase (AST), alanine
107 aminotransferase (ALT), total bilirubin, total protein, creatinine, and creatine kinase
108 (CK), with a Chemistry Analyzer (Beckman Coulter, AU5821). The serum LDH was
109 measured for healthy controls.

110 For LDH isoform analyses, 32 serum samples from 32 COVID-19 patients (11 non-
111 severe and 21 severe) were sent for electrophoresis with agarose gel electrophoretic
112 analyzer (SEBIA, HYDRASYS 2). ISO-LDH substrate and blocking buffer were
113 afterwards added to incubate for 20 min, respectively. The gel was scanned with the
114 same analyzer.

116 **Proteomic and metabolomic data set**

117 The proteomic and metabolomic data were extracted from our previous publication
118 ^[14]. Briefly, serum samples from COVID-19 patients were kept at 56°C for 30 min to
119 inactivate potential SARS-CoV-2. For proteomic experiments, inactivated serum
120 samples were processed into peptides, labeled with TMTpro 16plex chemical tags,
121 fractionated to 40 aliquots, and analyzed by LC-MS/MS. The proteomics data were
122 analyzed with Proteome Discoverer (Version 2.4.1.15, Thermo Fisher Scientific), with
123 the default parameter and a protein database composed of the Homo sapiens fasta
124 database (07 Jan 2020, UniProtKB), containing 20,412 reviewed protein sequences,
125 and the SARS-CoV-2 virus fasta (version NC_045512.2, NCBI). Targeted false
126 discovery rate (FDR) for peptide-spectrum match was set to 1% (strict) and 5%
127 (relaxed). Normalization was performed against the total peptide intensity. 894
128 proteins were quantified altogether. For metabolomic experiments, inactivated serum
129 samples were processed to collect metabolites, and divided into 4 fractions for 4
130 different modes of LC-MS/MS data acquisition, leading to characterization of 941
131 metabolites. The median coefficient of variance (CV) for proteomic and metabolomic
132 data were 10% and 5%, respectively, determined by pooled control samples in each
133 batch, as described previously ^[14]. The proteomics and metabolomics data could be
134 referenced from the previously publication in ProteomeXchange Consortium
135 (<https://www.iprox.org/>). Project ID: IPX0002106000 and IPX0002171000.

137 **Statistical analysis**

138 Statistical clinical data analyses were performed using SPSS software (version
139 22.0). Continuous variables were presented as median and interquartile range (IQR)
140 values, while categorical variables were shown as frequency and percentage. An
141 independent t-test was used for continuous variables when the data were normally
142 distributed; otherwise, the Mann-Whitney test was used. Chi-square test or Fisher's
143 exact test was used for categorical variables. Receiver operating characteristic (ROC)
144 analysis was used for the selection of the best intercept point. Prediction of disease
145 progression was obtained using the Cox proportional hazards model. Statistical
146 proteomic data analysis was performed using R (version 3.6.3). Missing values in the
147 proteomic data matrix were assigned as 0.01 unless otherwise mentioned. *P* values ≤
148 0.05 were considered statistically significant unless otherwise mentioned. Differential
149 protein expression was based on the cutoff: *P* values ≤ 0.05, $|\log_2FC| > 0.25$. Plotting

150 was performed with R (version 3.6.3).

151

152 **RESULTS AND DISCUSSION**

153 ***Demographic, clinical, and laboratory characteristics***

154 A total of 144 COVID-19 patients were enrolled in the study. Detailed
155 demographic, clinical, and laboratory characteristics of these patients on admission
156 were provided in Table 1. The median age was 47 years old, and 53.5% of them were
157 male. The severe patients account for 25% (36/144) of the group, were 10 years older
158 than the non-severe patients (55 vs. 45, $p < 0.001$), and were more likely to have fever
159 symptoms on admission ($p = 0.001$). Severe patients received higher percentages of
160 treatment in oxygen inhalation ($p < 0.001$), antibiotics ($p = 0.024$), glucocorticoid ($p <$
161 0.001), and intravenous gamma immunoglobulin ($p < 0.001$) than the non-severe
162 patients. These medications may have an impact on the patient blood metabolism and
163 may alter the COVID-19 microenvironment, which unfortunately could not be
164 rigorously examined in the current study due to the small sample size, awaiting future
165 investigations. The patients did not exhibit significant difference between severe and
166 non-severe groups in terms of gender unmentioned symptoms on admission, nor other
167 medical treatments ($p > 0.05$) as listed in Table 1.

168 Based on laboratory test results, a higher percentage of severe patients have
169 elevated levels of serum LDH that are above the upper limit of normal (ULN) value
170 than non-severe patients (58.3% vs. 7.4%, $p < 0.001$). Likewise, more severe patients
171 also showed higher level of alanine aminotransferase (ALT, $p = 0.023$), aspartate
172 aminotransferase (AST, $p < 0.001$), urea ($p = 0.004$), creatinine ($p = 0.029$), and
173 creatine kinase (CK, $p < 0.001$). We then compared their temporal changes at 7-day
174 intervals (Supplementary Table 1). LDH, CK, and creatinine showed continuous
175 decrease in the sera of severe patients, while only serum LDH showed a continuous
176 decrease in non-severe patients.

177 A Cox regression model was applied to evaluate the prognostic value of these
178 indicators (Supplementary Table 2). In the Cohort 1, LDH is the only indicator with
179 discrimination ability ($p < 0.001$) in the multivariate analysis, although LDH, AST,
180 and CK were determined in the univariate analysis with statistical significance ($p <$
181 0.001). We further validated the value of serum LDH in Cohort 2 and the data showed
182 significant discrimination ($p = 0.032$), suggesting that serum LDH could be a useful
183 prognostic biomarker.

184

185 ***Temporal characteristics of Serum LDH in COVID-19 patients***

186 We then assessed the effect of age and sex on the temporal serum LDH expression.
187 COVID-19 patients older than 60 years showed a higher serum LDH expression
188 throughout the disease course than that in younger patients (Figure 1A), probably due
189 to ageing and underlying diseases. Males expressed higher serum LDH levels than
190 that from females only during the initial hospitalization stage (within the first week)
191 (Figure 1B). Serum LDH levels became comparable between COVID-19 patients and
192 healthy controls (median values: 177 U/L above 60 years old and 152 U/L below 60
193 years old; 154 U/L for males and 158.5 U/L for females) after three weeks.

194 We compared the median values of serum LDH levels from the initial admission
195 stage (1-3 days after admission) and discharge stage (1-3 days before discharge), in a
196 sub-cohort of recovered patients that were discharged by the end of follow-up. (total:
197 $n=49$; severe: $n=13$; non-severe: $n=36$) (Figure 1C). Serum LDH levels were
198 significantly higher in the severe patient group, particularly on admission ($p < 0.01$).

199 We analyzed serum LDH isoform expression from 32 patients upon admission
200 (severe: n=22; non-severe: n=11) (Figure 1D) and found that LDH-2, LDH-4 and
201 LDH-5 were significantly higher in the sera of severe COVID-19 patients. LDH-1 in
202 contrast was not dysregulated. LDH-4 and LDH-5 mainly contribute to pyruvate
203 fermentation under hypoxic conditions, while LDH-1 favors the opposite direction of
204 the reversible reaction ^[15]. These data suggest anaerobic glycolysis metabolism in
205 severe patients.

206 To better understand the temporal dynamics of serum LDH expression over the
207 disease course, we next monitored the serum LDH level from day 1 on admission till
208 day 21 at a 3-day interval (Figure 1E). As to the non-severe patient group, the serum
209 LDH level was slightly higher on admission while declining slowly over the
210 hospitalization period. The serum LDH levels in the severe group comparatively were
211 significantly higher upon admission, with a prominent variance range. They dropped
212 significantly from 3rd to 9th day as the patients were taking medical care and by the
213 21st day fell below the initial serum LDH levels in the non-severe group.

214

215 ***Classification of low- and high-risk patients based on serum LDH levels***

216 To establish a cohort-specific serum LDH expression threshold as a risk indicator,
217 we took patient severity (severe vs. non-severe) as the dichotomous variable and
218 conducted the receiver operating characteristic (ROC) analysis on the serum LDH
219 expression levels on admission. The area under curve (AUC) was 0.864 (Figure 1F),
220 confirming the discriminative power of serum LDH. The serum LDH level
221 corresponding to the maximum Youden index was determined as 247 U/L, within the
222 threshold to determine serum LDH abnormality from past reports (240-253.2 U/L) ^[13].

223 Fourteen characteristic patients within the cohort were selected and divided into
224 two groups for closer inspection (Figure 1H). The low-risk (LR) group consists of
225 seven non-severe patients with serum LDH expressions below 247 U/L since
226 admission except for one exceptional detection (LR4, 5th day, 306 U/L). The high-risk
227 (HR) group are composed of six severe patients with on admission serum LDH levels
228 above 247 U/L, and one severe patient with serum LDH levels below the threshold
229 throughout hospitalization (HR1). We attribute this to the relatively late first sampling
230 timepoint (8th day), given that serum LDH levels from all the patients started at a
231 relatively high level and declined over time. Patient HR3 and patient HR7 in
232 particular had exceptionally high serum LDH levels (> 450 U/L) upon admission but
233 dropped dramatically within 10 days. We inspected the detailed medical records of the
234 14 patients (Table 2). COVID-19 patients with comorbidities including hypertension,
235 chronic HBV infection, and diabetes tend to be severe patients in the HR group, in
236 consistent with the literature ^[16,17].

237

238 ***Quantitative proteomics and metabolomics uncover dysregulated molecules 239 associated with elevated serum LDH***

240 The serum proteomic and metabolomic datasets of the HR and LR group patients
241 were extracted from a collateral project ^[14]. 78.6% (11/14) of the patient sera were
242 sampled during the first week on admission (Table 2), herein representing the stage
243 when serum LDH levels exhibited sharp difference between the LR and HR groups.
244 For the proteomic dataset, the Student's *t*-test highlighted 34 proteins as differentially
245 expressed ($p < 0.05$) between HR and LR groups (Figure 2A, upper panel), 26 of
246 which were up-regulated. Pathway enrichment analysis using Metascape ^[18] showed
247 these proteins conduct three major immune-related activities including acute
248 inflammatory responses (GO:0002526, $p < 0.001$), platelet degranulation

249 (GO:0002576, $p < 0.001$) and regulation of complement cascade (R-HSA-977606, $p <$
250 0.001) (Figure 2A and Supplementary Fig. 2A). Additional analyses using Ingenuity
251 Pathway Analysis (IPA) nominated acute phase response signaling as the most
252 activated immune-related pathway (Supplementary Fig. 2C) in HR patients. These
253 findings were in consistence with the prominent immune behaviors (Supplementary
254 Fig. 1B) as we have previously reported in COVID-19 patients with different severity
255 ^[14]. Moreover, blood coagulation (GO: 007596, $p < 0.001$) was significantly enriched
256 (Supplementary Fig. 2A and 2C). This pathway has been reported to be altered in
257 COVID-19, and associated with interleukin-6 (IL-6)^[19]. Our data showed
258 upregulation of acute phase proteins (SAA1, ORM1, AGT, and SERPINA3),
259 complement subunits (C9, C6, and CFI), and LDH subtypes (LDHA and LDHB) in
260 the HR group (Figure 2B). Thirteen of the differentiated proteins were mapped into a
261 network wherein key regulators were focused (Figure 2C). Within them, pro-
262 inflammatory cytokine IL-6 has been widely recognized as a risk factor for COVID-
263 19 ^[19-23] and clinically observed to be positively correlated with serum LDH levels
264 ^[24]. IL-6 can activate TP53, which facilitates cell apoptosis and could enhance LDHA
265 expression in blood. Multiple COVID-19 studies involving IL-6 agree with our
266 profiling ^[19,25]. This network also includes CCAAT/enhancer-binding protein beta
267 (CEBPB) which mediates immune and inflammatory responses ^[26], and sterol
268 regulatory element binding transcription factor 1 (SREBF1) which regulates lipid
269 metabolisms that has been reported dysregulated in severe COVID-19 patients ^[14].
270 Taken together, the proteomic difference between LR and HR patients reflected
271 different host responses between the non-severe and severe COVID-19 patients.

272 Of the 34 differentially expressed metabolites listed in Supplementary Fig. 3A,
273 88.2% (30/34) were upregulated, and 52.9% (18/34) were lipids. Within them, 7-
274 hydroxycholesterol (beta) mediates oxidative stress and induces cell apoptosis. It was
275 elevated during hepatitis B virus (HBV) and hepatitis C virus (HCV) infections ^[27]
276 (Fig 2A and Fig 2B, lower panel). Further calibration and absolute quantification of
277 these lipids would enable in-depth characterization of lipids and their variants. The
278 protein-metabolite joint network generated using IPA (Supplementary Fig. 3B)
279 proposed two upstream molecules to regulate LDHA expression, including hypoxia-
280 inducible factor 1 (HIF1) that mediates hypoxic and inflammatory microenvironments
281 ^[28] and fibronectin 1 (FN1) that involves COVID-19 lung fibrosis ^[29]. The
282 dysregulated metabolites further consolidate disturbed host responses in association
283 with serum LDH increase uncovered by the proteomic data.

284

285 ***Protein and metabolite change in patients with exceptionally high serum LDH***

286 Next, we narrowed our focus to the two patients with exceptionally high serum
287 LDH levels on admission (HR3 and HR7, HR outliers), and compared their proteomic
288 patterns with the other HR patients (Figure 3A). 38 proteins including LDHA and
289 LDHB were differentially expressed ($p < 0.05$, Figure 3A). Metascape pathway
290 enrichment nominated 23 proteins associated with immune system process
291 (GO:0002376, $p < 0.001$) and 21 proteins associated with metabolic process
292 (GO:0008152, $p < 0.001$) (Supplementary Fig 4B). The top enriched immune-related
293 pathways are the activation of immune response (GO:0002253, $p < 0.001$) and
294 humoral immunity response (GO:0006959, $p < 0.001$), while the top enriched
295 metabolic pathway relates to cofactors (R-HSA-89 78934, $p < 0.001$) (Supplementary
296 Fig. 4A). IPA analysis detailed the top metabolic functions as protein ubiquitination
297 pathway and pyruvate fermentation to lactate (Supplementary Fig 4C). Especially, the
298 HIF1 α signaling pathway showed a drastic activation in the HR (outliers) group. As

299 for characteristic proteins in HR (outliers), our data uncovered a dysregulated protein
300 group which includes five up-regulated proteasome subunits, namely PSMA3,
301 PSMA4, PSMA5, PSMB1, and PSMB3 (Figure 3B), possibly due to cell apoptosis [30]
302 from organ/tissue damage. They are the mediators of protein ubiquitination and
303 associate with NF- κ B signaling (GO:0038061, $p < 0.001$). Six of the seven
304 differentially expressed immunoglobulin residues (IGHV3-43, IGHV3-30-5, IGKV1-
305 5, IGLV1-36, IGKV1-17, and IGKV2-24) (Supplementary Fig. 5A) were up-regulated
306 in HR (outliers), suggesting that humoral immunity at the point of detection was
307 suppressed or not activated. For the other up-regulated proteins in HR (outliers)
308 (Figure 3B), CES1 is a hepatic protein and its release in blood suggests liver injuries.
309 Protein disulfide-isomerase (P4HB) was reported to up-rise in response to hypoxia
310 [31]. GAPDH could enhance HIF activity [32] via NF- κ B induction activated in hypoxia
311 [33], which contributes to heat shock protein 90-alpha (HSP90AA1) upregulation [34] to
312 form protein complexes with Hif1 α . Dipeptidyl peptidase 4 (DPP4), also known as
313 CD26, has been nominated as a potential critical marker in infection susceptibility [35],
314 and its inhibition has been proposed to reduce COVID-19 patient severity [36]. DPP4 is
315 also a downstream factor to mark HIF pathway induction [37]. Especially, the down-
316 regulated protein in HR (outliers) includes CPB2 as a basic carboxypeptidase that
317 suppresses complement system-mediated inflammation [38]. Its deficiency could lead
318 to accelerated acute lung injuries [39]. 84.6% (11/13) of the dysregulated metabolites
319 were lipids (Supplementary Fig. 5B), suggesting disturbed lipid metabolism
320 accompanied with serum LDH changes. The network analysis (Supplementary Fig.
321 5C) further proposed LDH elevation to be associated with HSP90AA1 and
322 proteasomes.

323

324 ***Serum LDH elevation might be driven by tissue injuries and hypoxia***

325 Taking together all the perturbed molecules as highlighted above (Figure 2B and
326 3B), we propose a putative working model for the serum LDH elevation in COVID-
327 19 patients (Figure 3C). On the one hand, the inflammation processes triggered by the
328 host immune system induce apoptosis of the infected cells, leading to the release of
329 intracellular LDH into the blood. In high-risk cases, these immune activities result in
330 over-reactive inflammation processes (like “cytokine storm”) [40], thereby releasing
331 higher levels of serum LDH from multiple organs/tissues [10]. On the other hand,
332 oxygen homeostasis was disturbed in severe COVID-19 patients [12]. Hypoxia
333 reactions occur to accumulate lactate via glycolysis. LDH can balance lactate
334 secretion via pyruvate fermentation and a series of metabolic regulation
335 (Supplementary Fig. 4A and 4C) to maintain cellular homeostasis [41]. The activated
336 NF- κ B and HIF pathways in hypoxia conditions could also induce inflammatory
337 responses [42].

338

339 **CONCLUDING REMARKS**

340 Here we systematically investigated serum LDH elevation in COVID-19 patients.
341 We thoroughly inspected both clinical and molecular profiles of 144 COVID-19
342 patients. We confirmed serum LDH as the best independent risk indicator, and further
343 optimized a threshold of 247 U/L for stratifying COVID-19 patients based on the
344 serum LDH level. Our data showed that the serum LDH declined thereafter, patients
345 with serum LDH levels higher than the threshold on admission are prone to severe
346 conditions, hence determined as high-risk (HR) patients, and those lower than the
347 threshold as low-risk (LR) patients.

348 Proteomic differences between LR and HR groups exposed a list of dysregulated
349 host responses. Among them, acute inflammatory responses, platelet degranulation
350 and complement cascade have been reported in previous studies comparing severe and
351 non-severe COVID-19 patients [14,43]. Blood coagulation has been highlighted in
352 another report that compares COVID-19 patients with high and low IL-6 levels [44].
353 Immune behaviors including activation of immune response and humoral immune
354 response were further enriched during the intra-comparison within HR patients,
355 suggesting that the immune behaviors are closely related to serum LDH expression.
356 Proteomic profiling also highlighted a list of hypoxia related proteins and functions,
357 including P4HB, DPP4, GAPDH, HSP90AA1, NF- κ B and HIF signaling, suggesting
358 that hypoxia might have contributed to elevated LDH. The metabolomic profiling
359 complements findings on the proteomic level and further emphasizes dysregulated
360 lipid metabolism. Taken together, we propose that elevation of serum LDH might
361 attribute to inflammation-related tissue injuries and hypoxia-related metabolism.

362 This study is limited by several factors. Firstly, this is a single-center study with a
363 relatively small patient cohort due to difficulties of sample collection, therefore
364 subject to experimental bias. Also, the standard inactivation procedures for COVID-
365 19 serum to minimize the risk of infection may have some impact on the characterized
366 samples. Moreover, proteome data from only 14 individuals were acquired, from
367 which only 2 patients were determined as high-risk group outliers for comparative
368 analysis. We could not obtain the samples from different patients at the identical time
369 points. And due to the small sample size, multiple testing wasn't performed for
370 molecular analyses, therefore the statistical power from the proteomic data has to be
371 interpreted with caution. It is worth noting that serum LDH elevation is not specific to
372 COVID-19 disease [45]. Further studies should conduct clinical validation on larger
373 cohorts, and compare the molecular differences including control patients with other
374 diseases with similar symptoms. Targeted approaches would also be required to
375 validate our findings for diagnostic purposes.

376

377 **CONFLICT OF INTERESTS**

378 The research group of T.G. is partly supported by Tencent, Thermo Fisher
379 Scientific, SCIEEX, and Pressure Biosciences Inc. T.G. is a shareholder of Westlake
380 Omics Inc. G.R. is an employee of Westlake Omics Inc.

381 **ACKNOWLEDGMENTS**

382 This work was supported by grants from National Key R&D Program of China
383 (No. 2020YFE0202200), National Natural Science Foundation of China (81972492,
384 21904107, 81672086, 82072333), Zhejiang Provincial Natural Science Foundation for
385 Distinguished Young Scholars (LR19C050001), Hangzhou Agriculture and Society
386 Advancement Program (20190101A04), Zhejiang Provincial Natural Science
387 Foundation of China (LQ19H100001), Zhejiang Medical and Health Science and
388 Technology Plan (2021KY394), Westlake Education Foundation, and Tencent
389 Foundation. We thank Westlake University Supercomputer Center for assistance in
390 data storage and computation.

391 **References**

- 392 [1] Huang, C., Wang, Y., Li, X., Ren, L., Zhao, J., Hu, Y., . . . Cao, B. (2020). Clinical features of patients
393 infected with 2019 novel coronavirus in Wuhan, China. *Lancet (London, England)*,
394 *395*(10223), 497-506. doi: 10.1016/S0140-6736(20)30183-5
- 395 [2] Chen, N., Zhou, M., Dong, X., Qu, J., Gong, F., Han, Y., . . . Zhang, L. (2020). Epidemiological and
396 clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China:
397 a descriptive study. *Lancet (London, England)*, *395*(10223), 507-513. doi: 10.1016/S0140-
398 6736(20)30211-7
- 399 [3] Hui, D. S.-C., Wong, P.-C., & Wang, C. (2003). SARS: clinical features and diagnosis. *Respirology*
400 (*Carlton, Vic.*), *8 Suppl*(Suppl 1), S20-S24. doi: 10.1046/j.1440-1843.2003.00520.x
- 401 [4] Huang, E.-J., Kuo, W.-W., Chen, Y.-J., Chen, T.-H., Chang, M.-H., Lu, M.-C., . . . Lee, S.-D. (2006).
402 Homocysteine and other biochemical parameters in Type 2 diabetes mellitus with
403 different diabetic duration or diabetic retinopathy. *Clinica Chimica Acta*, *366*(1), 293-298.
404 doi: <https://doi.org/10.1016/j.cca.2005.10.025>
- 405 [5] Ding, J., Karp, J. E., & Emadi, A. (2017). Elevated lactate dehydrogenase (LDH) can be a marker
406 of immune suppression in cancer: Interplay between hematologic and solid neoplastic
407 clones and their microenvironments. *Cancer Biomark*, *19*(4), 353-363. doi: 10.3233/cbm-
408 160336
- 409 [6] Wan, S., Xiang, Y., Fang, W., Zheng, Y., Li, B., Hu, Y., . . . Yang, R. (2020). Clinical features and
410 treatment of COVID-19 patients in northeast Chongqing. *Journal of medical virology*,
411 *92*(7), 797-806. doi: 10.1002/jmv.25783
- 412 [7] Yuan, J., Zou, R., Zeng, L., Kou, S., Lan, J., Li, X., . . . Wang, Z. (2020). The correlation between
413 viral clearance and biochemical outcomes of 94 COVID-19 infected discharged patients.
414 *Inflammation research : official journal of the European Histamine Research Society ... [et*
415 *al.]*, *69*(6), 599-606. doi: 10.1007/s00011-020-01342-0
- 416 [8] Zhou, P., Yang, X.-L., Wang, X.-G., Hu, B., Zhang, L., Zhang, W., . . . Huang, C.-L. (2020).
417 Discovery of a novel coronavirus associated with the recent pneumonia outbreak in
418 humans and its potential bat origin. *bioRxiv*.
- 419 [9] Chen, G., Wu, D., Guo, W., Cao, Y., Huang, D., Wang, H., . . . Ning, Q. (2020). Clinical and
420 immunological features of severe and moderate coronavirus disease 2019. *The Journal of*
421 *clinical investigation*, *130*(5), 2620-2629. doi: 10.1172/JCI137244
- 422 [10] Shi, J., Li, Y., Zhou, X., Zhang, Q., Ye, X., Wu, Z., . . . Zhang, W. (2020). Lactate dehydrogenase
423 and susceptibility to deterioration of mild COVID-19 patients: a multicenter nested case-
424 control study. *BMC medicine*, *18*(1), 168-168. doi: 10.1186/s12916-020-01633-7
- 425 [11] Poggiali, E., Zaino, D., Immovilli, P., Rovero, L., Losi, G., Dacrema, A., . . . Terracciano, C. (2020).
426 Lactate dehydrogenase and C-reactive protein as predictors of respiratory failure in
427 CoVID-19 patients. *Clinica chimica acta; international journal of clinical chemistry*, *509*,
428 135-138. doi: 10.1016/j.cca.2020.06.012
- 429 [12] Han, Y., Zhang, H., Mu, S., Wei, W., Jin, C., Tong, C., . . . Gu, G. (2020). Lactate dehydrogenase,
430 an independent risk factor of severe COVID-19 patients: a retrospective and observational
431 study. *Aging*, *12*(12), 11245-11258. doi: 10.18632/aging.103372
- 432 [13] Henry, B. M., Aggarwal, G., Wong, J., Benoit, S., Vikse, J., Plebani, M., & Lippi, G. (2020). Lactate
433 dehydrogenase levels predict coronavirus disease 2019 (COVID-19) severity and mortality:
434 A pooled analysis. *The American Journal of Emergency Medicine*, *38*(9), 1722-1726. doi:
435 10.1016/j.ajem.2020.05.073
- 436 [14] Shen, B., Yi, X., Sun, Y., Bi, X., Du, J., Zhang, C., . . . Guo, T. (2020). Proteomic and Metabolomic
437 Characterization of COVID-19 Patient Sera. *Cell*, *182*(1), 59-72.e15. doi:
438 10.1016/j.cell.2020.05.032
- 439 [15] Augoff, K., Hryniewicz-Jankowska, A., & Tabola, R. (2015). Lactate dehydrogenase 5: An old
440 friend and a new hope in the war on cancer. *Cancer Letters*, *358*(1), 1-7. doi:
441 <https://doi.org/10.1016/j.canlet.2014.12.035>

- 442 [16] Zheng, Z., Peng, F., Xu, B., Zhao, J., Liu, H., Peng, J., . . . Tang, W. (2020). Risk factors of critical
443 & mortal COVID-19 cases: A systematic literature review and meta-analysis. *J Infect*, *81*(2),
444 e16-e25. doi: 10.1016/j.jinf.2020.04.021
- 445 [17] Zou, X., Fang, M., Li, S., Wu, L., Gao, B., Gao, H., . . . Huang, J. (2020). Characteristics of Liver
446 Function in Patients With SARS-CoV-2 and Chronic HBV Coinfection. *Clin Gastroenterol*
447 *Hepatol*. doi: 10.1016/j.cgh.2020.06.017
- 448 [18] Zhou, Y., Zhou, B., Pache, L., Chang, M., Khodabakhshi, A. H., Tanaseichuk, O., . . . Chanda, S.
449 K. (2019). Metascape provides a biologist-oriented resource for the analysis of systems-
450 level datasets. *Nat Commun*, *10*(1), 1523. doi: 10.1038/s41467-019-09234-6
- 451 [19] D'Alessandro, A., Thomas, T., Dzieciatkowska, M., Hill, R. C., Francis, R. O., Hudson, K. E., . . .
452 Hansen, K. C. (2020). Serum Proteomics in COVID-19 Patients: Altered Coagulation and
453 Complement Status as a Function of IL-6 Level. *Journal of Proteome Research*, *19*(11),
454 4417-4427. doi: 10.1021/acs.jproteome.0c00365
- 455 [20] Tian, J., Yuan, X., Xiao, J., Zhong, Q., Yang, C., Liu, B., . . . Wang, Z. (2020). Clinical characteristics
456 and risk factors associated with COVID-19 disease severity in patients with cancer in
457 Wuhan, China: a multicentre, retrospective, cohort study. *The Lancet. Oncology*, *21*(7),
458 893-903. doi: 10.1016/S1470-2045(20)30309-0
- 459 [21] Liu, F., Li, L., Xu, M., Wu, J., Luo, D., Zhu, Y., . . . Zhou, X. (2020). Prognostic value of interleukin-
460 6, C-reactive protein, and procalcitonin in patients with COVID-19. *Journal of clinical*
461 *virology : the official publication of the Pan American Society for Clinical Virology*, *127*,
462 104370-104370. doi: 10.1016/j.jcv.2020.104370
- 463 [22] Santa Cruz, A., Mendes-Frias, A., Oliveira, A. I., Dias, L., Matos, A. R., Carvalho, A., . . . Silvestre,
464 R. (2021). Interleukin-6 Is a Biomarker for the Development of Fatal Severe Acute
465 Respiratory Syndrome Coronavirus 2 Pneumonia. *Frontiers in Immunology*, *12*, 613422.
466 doi: 10.3389/fimmu.2021.613422
- 467 [23] Aziz, M., Fatima, R., & Assaly, R. (2020). Elevated interleukin-6 and severe COVID-19: A meta-
468 analysis. *Journal of medical virology*, *92*(11), 2283-2285. doi: 10.1002/jmv.25948
- 469 [24] Liu, T., Zhang, J., Yang, Y., Ma, H., Li, Z., Zhang, J., . . . Yi, J. (2020). The role of interleukin-6 in
470 monitoring severe case of coronavirus disease 2019. *EMBO molecular medicine*, *12*(7),
471 e12421-e12421. doi: 10.15252/emmm.202012421
- 472 [25] Hadjadj, J., Yatim, N., Barnabei, L., Corneau, A., Boussier, J., Smith, N., . . . Terrier, B. (2020).
473 Impaired type I interferon activity and inflammatory responses in severe COVID-19
474 patients. *Science*, *369*(6504), 718-724. doi: 10.1126/science.abc6027
- 475 [26] Kinoshita, S., Akira, S., & Kishimoto, T. (1992). A member of the C/EBP family, NF-IL6 beta,
476 forms a heterodimer and transcriptionally synergizes with NF-IL6. *Proc Natl Acad Sci U S*
477 *A*, *89*(4), 1473-1476. doi: 10.1073/pnas.89.4.1473
- 478 [27] Yoshida, Y., Kodai, S., Takemura, S., Minamiyama, Y., & Niki, E. (2008). Simultaneous
479 measurement of F2-isoprostane, hydroxyoctadecadienoic acid, hydroxyeicosatetraenoic
480 acid, and hydroxycholesterols from physiological samples. *Anal Biochem*, *379*(1), 105-115.
481 doi: 10.1016/j.ab.2008.04.028
- 482 [28] Jahani, M., Dokaneheifard, S., & Mansouri, K. (2020). Hypoxia: A key feature of COVID-19
483 launching activation of HIF-1 and cytokine storm. *Journal of inflammation (London,*
484 *England)*, *17*, 33-33. doi: 10.1186/s12950-020-00263-3
- 485 [29] Xu, J., Xu, X., Jiang, L., Dua, K., Hansbro, P. M., & Liu, G. (2020). SARS-CoV-2 induces
486 transcriptional signatures in human lung epithelial cells that promote lung fibrosis. *Respir*
487 *Res*, *21*(1), 182. doi: 10.1186/s12931-020-01445-6
- 488 [30] Weathington, N. M., & Mallampalli, R. K. (2013). New insights on the function of SCF ubiquitin
489 E3 ligases in the lung. *Cell Signal*, *25*(9), 1792-1798. doi: 10.1016/j.cellsig.2013.05.003
- 490 [31] Ko, H. S., Uehara, T., & Nomura, Y. (2002). Role of ubiquilin associated with protein-disulfide
491 isomerase in the endoplasmic reticulum in stress-induced apoptotic cell death. *J Biol*
492 *Chem*, *277*(38), 35386-35392. doi: 10.1074/jbc.M203412200

- 493 [32] Chiche, J., Pommier, S., Beneteau, M., Mondragon, L., Meynet, O., Zunino, B., . . . Ricci, J. E.
494 (2015). GAPDH enhances the aggressiveness and the vascularization of non-Hodgkin's B
495 lymphomas via NF-kappaB-dependent induction of HIF-1alpha. *Leukemia*, *29*(5), 1163-
496 1176. doi: 10.1038/leu.2014.324
- 497 [33] Li, Y., Yang, L., Dong, L., Yang, Z. W., Zhang, J., Zhang, S. L., . . . Li, S. Q. (2019). Crosstalk
498 between the Akt/mTORC1 and NF-kappaB signaling pathways promotes hypoxia-
499 induced pulmonary hypertension by increasing DPP4 expression in PSMCs. *Acta*
500 *Pharmacol Sin*, *40*(10), 1322-1333. doi: 10.1038/s41401-019-0272-2
- 501 [34] Zuehlke, A. D., Beebe, K., Neckers, L., & Prince, T. (2015). Regulation and function of the human
502 HSP90AA1 gene. *Gene*, *570*(1), 8-16. doi: 10.1016/j.gene.2015.06.018
- 503 [35] Senapati, S., Kumar, S., Singh, A. K., Banerjee, P., & Bhagavatula, S. (2020). Assessment of risk
504 conferred by coding and regulatory variations of TMPRSS2 and CD26 in susceptibility to
505 SARS-CoV-2 infection in human. *J Genet*, *99*(1). doi: 10.1007/s12041-020-01217-7
- 506 [36] Solerte, S. B., Di Sabatino, A., Galli, M., & Fiorina, P. (2020). Dipeptidyl peptidase-4 (DPP4)
507 inhibition in COVID-19. *Acta Diabetol*, *57*(7), 779-783. doi: 10.1007/s00592-020-01539-
508 z
- 509 [37] Dang, D. T., Chun, S. Y., Burkitt, K., Abe, M., Chen, S., Havre, P., . . . Dang, L. H. (2008). Hypoxia-
510 inducible factor-1 target genes as indicators of tumor vessel response to vascular
511 endothelial growth factor inhibition. *Cancer Res*, *68*(6), 1872-1880. doi: 10.1158/0008-
512 5472.can-07-1589
- 513 [38] Leung, L. L. K., & Morser, J. (2018). Carboxypeptidase B2 and carboxypeptidase N in the
514 crosstalk between coagulation, thrombosis, inflammation, and innate immunity. *J Thromb*
515 *Haemost*. doi: 10.1111/jth.14199
- 516 [39] Naito, M., Taguchi, O., Kobayashi, T., Takagi, T., D'Alessandro-Gabazza, C. N., Matsushima,
517 Y., . . . Gabazza, E. C. (2013). Thrombin-activatable fibrinolysis inhibitor protects against
518 acute lung injury by inhibiting the complement system. *Am J Respir Cell Mol Biol*, *49*(4),
519 646-653. doi: 10.1165/rcmb.2012-0454OC
- 520 [40] Mehta, P., McAuley, D. F., Brown, M., Sanchez, E., Tattersall, R. S., & Manson, J. J. (2020).
521 COVID-19: consider cytokine storm syndromes and immunosuppression. *Lancet (London,*
522 *England)*, *395*(10229), 1033-1034. doi: 10.1016/s0140-6736(20)30628-0
- 523 [41] Lee, D. C., Sohn, H. A., Park, Z. Y., Oh, S., Kang, Y. K., Lee, K. M., . . . Yeom, Y. I. (2015). A lactate-
524 induced response to hypoxia. *Cell*, *161*(3), 595-609. doi: 10.1016/j.cell.2015.03.011
- 525 [42] D'Ignazio, L., Bandarra, D., & Rocha, S. (2016). NF-kappaB and HIF crosstalk in immune
526 responses. *FEBS J*, *283*(3), 413-424. doi: 10.1111/febs.13578
- 527 [43] Messner, C. B., Demichev, V., Wendisch, D., Michalick, L., White, M., Freiwald, A., . . . Ralser, M.
528 (2020). Ultra-High-Throughput Clinical Proteomics Reveals Classifiers of COVID-19
529 Infection. *Cell Systems*, *11*(1), 11-24.e14. doi: <https://doi.org/10.1016/j.cels.2020.05.012>
- 530 [44] D'Alessandro, A., Thomas, T., Dzieciatkowska, M., Hill, R. C., Francis, R. O., Hudson, K. E., . . .
531 Hansen, K. C. (2020). Serum Proteomics in COVID-19 Patients: Altered Coagulation and
532 Complement Status as a Function of IL-6 Level. *Journal of Proteome Research*. doi:
533 10.1021/acs.jproteome.0c00365
- 534 [45] Hui, D. S., Wong, P. C., & Wang, C. (2003). SARS: clinical features and diagnosis. *Respirology*,
535 *8 Suppl*(Suppl 1), S20-24. doi: 10.1046/j.1440-1843.2003.00520.x

536
537
538
539
540
541
542

Table 1 Clinical characteristics and Laboratorial indexes of COVID-19 patients.

| Characteristics | Total (N=144) | Non-severe (N=108) | Severe (N=36) | <i>p</i> value |
|------------------------------------|---------------|--------------------|---------------|----------------|
| Age, years | | | | |
| median (IQR) | 47 (38-56) | 45 (37-54) | 55 (48-65) | 0.000 |
| Sex, Male | 77 (53.5) | 57 (52.8) | 20(55.6) | 0.772 |
| Symptoms on Admission | | | | |
| Fever, % | 104 (72.2) | 70(64.8) | 34 (94.4) | 0.001 |
| Pharyngalgia, % | 17 (11.8) | 15 (13.9) | 2 (5.6) | 0.180 |
| Cough, % | 65 (45.1) | 47 (43.5) | 18 (50.0) | 0.499 |
| Expectoration, % | 26 (18.1) | 19 (17.6) | 7 (19.4) | 0.802 |
| Tiredness, % | 16 (11.1) | 10 (9.3) | 6 (16.7) | 0.221 |
| Headache, % | 16 (11.1) | 9 (8.3) | 7 (19.4) | 0.066 |
| Medical Treatment | | | | |
| Oxygen inhalation, % | 97 (67.4) | 63 (58.3) | 34 (94.4) | 0.000 |
| Antibiotics, % | 26 (18.1) | 15 (13.9) | 11 (30.6) | 0.024 |
| Antivirus, % | 144 (100) | 108 (100) | 36 (100) | 1.000 |
| Glucocorticoid, % | 37 (25.7) | 13 (12.0) | 24 (66.7) | 0.000 |
| Gamma Immunoglobulin, % | 33 (22.9) | 7 (6.5) | 26 (72.2) | 0.000 |
| Laboratorial Indexes | | | | |
| LDH (ULN) ^a | | | | 0.000 |
| Low or normal | 115(79.9) | 100 (92.6) | 15 (41.7) | |
| High | 29 (20.1) | 8 (7.4) | 21 (58.3) | |
| ALT (ULN) ^b | | | | 0.023 |
| Low or normal | 130 (90.3) | 101 (93.5) | 29 (80.6) | |
| High | 14 (9.7) | 7 (6.5) | 7 (19.4) | |
| AST (ULN) ^c | | | | 0.000 |
| Low or normal | 125(86.8) | 101 (93.5) | 24 (66.7) | |
| High | 19 (13.2) | 7 (6.5) | 12 (33.3) | |
| Total bilirubin (ULN) ^d | | | | 0.422 |
| Low or normal | 122(84.7) | 93(86.1) | 29 (80.6) | |
| High | 22 (15.3) | 15 (13.9) | 7 (19.4) | |
| Total protein (LLN) ^e | | | | 0.477 |
| High or normal | 114 (79.2) | 87 (80.6) | 27 (75.0) | |
| Low | 30 (20.8) | 21 (19.4) | 9 (25.0) | |
| Urea (ULN) ^f | | | | 0.004 |
| Low or normal | 137 (95.1) | 106 (98.1) | 31 (86.1) | |
| High | 7 (4.9) | 2 (1.9) | 5 (13.9) | |
| Creatinine (ULN) ^g | | | | 0.029 |

| | | | | |
|------------------------------------|------------|------------|-----------|-------|
| Low or normal | 135 (93.8) | 104 (96.3) | 31 (86.1) | |
| High | 9 (6.3) | 4 (3.7) | 5 (13.9) | |
| Creatine kinase (ULN) ^h | | | | 0.000 |
| Low or normal | 123 (85.4) | 99 (91.7) | 24 (66.7) | |
| High | 21 (14.6) | 9 (8.3) | 12 (33.3) | |

544 Abbreviations: LDH, Lactate dehydrogenase; AST, aspartate aminotransferase; ALT, Alanine
 545 aminotransferase.

546 ^a ULN of LDH for male and female are 285 and 227 U/L, respectively.

547 ^b ULN of ALT for male and female are 50 and 40 U/L, respectively.

548 ^c ULN of AST for male and female are 40 and 35 U/L, respectively.

549 ^d ULN of total bilirubin is 20.5 µmol/L.

550 ^e LLN of total protein is 65 g/L.

551 ^f ULN of urea for male and female are 8 and 8.8 U/L, respectively.

552 ^g ULN of creatinine for male and female are 104 and 84 µmol/L, respectively.

553 ^h ULN of CK for male and female are 172 and 140 U/L, respectively.

554 Abbreviations: ULN, upper limit of normal; LLN, lower limit of normal; LDH, Lactate dehydrogenase;

555 AST, aspartate aminotransferase; ALT, Alanine aminotransferase.


556 **Table 2 Medical records of temporal change associated severe patients.**

| Patient Num. | HR1 | HR2 | HR3 | HR4 | HR5 | HR6 | HR7 | LR1 | LR2 | LR3 | LR4 | LR5 | LR6 | LR7 |
|--------------------------------------|-----------------------------|--------------------------------|-----|---|--------------------------------------|--|---|---------------------------------|-----|-----|-----|-----|-----|---|
| Sex | F | M | F | M | M | M | M | M | F | M | F | M | M | M |
| Age | >60 | >60 | >60 | ≤60 | ≤60 | ≤60 | ≤60 | >60 | ≤60 | >60 | ≤60 | ≤60 | ≤60 | ≤60 |
| Days for Admission | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
| Days for Progression to Severe Stage | 2 | 1 | 4 | 0* | 1 | 1 | 3 | | | | | | | |
| Days for Proteomic Sampling | 5 | 2 | 2 | 2 | 2 | 1 | 1 | 2 | 6 | 4 | 5 | 4 | 11 | 1 |
| Days for Metabolomic Sampling | 8 | 2 | 2 | 11 | 3 | 1 | 1 | 2 | 1 | 3 | 1 | 1 | 1 | 1 |
| Basic Diseases | Left breast tumor resection | Benign thyroid tumor resection | | Hypertension, gout arthritis, hyperuricemia, chronic renal insufficiency for 14 years | High blood pressure, type 2 diabetes | Chronic viral hepatitis b more than 20 years, hypothyroidism 5 years | Hepatitis b virus infection more than 10 years ago. | Type 2 diabetes, hyperlipidemia | | | | | | Hepatitis b virus infection 20 years, type 2 diabetes |

557 *: Patient HR4 was diagnosed as severe before admission to Taizhou Hospital.

558


559 **Figure 1 Serum LDH expression levels in the study cohort.** A-B) Serum LDH
560 expression levels in different time courses grouped by age and sex. *, $0.01 < p \leq 0.05$; **,
561 $0.005 < p \leq 0.01$; ***, $0.001 < p \leq 0.005$; ****, $p \leq 0.001$. C) Serum LDH expression levels
562 of severe and non-severe patients during the admission and discharge stage. D)
563 Expression of serum LDH isoforms during the admission stage. E) Serum LDH
564 expression levels of severe and non-severe patients in time courses at the 3-day interval.
565 F) Receiver operating characteristic (ROC) of the study cohort when setting LDH
566 expression level cutoff as 247 U/L. G) Individual inspection of 14 patients' LDH
567 expression dynamics. Yellow dash line, Patient HR1; Purple dash line, Patient LR4.
568



569
570

571


572 **Figure 2 Molecular differences between low- and high-risk patients.** A) Heatmap of
 573 34 differentially expressed proteins and two differentially expressed metabolites. LR,
 574 low-risk patients. HR, high-risk patients. B) Boxplots of nine selected differentially
 575 expressed proteins and two selected differentially expressed metabolites. C) Protein
 576 network including 12 selected differentially expressed proteins.



577

578

579 **Figure 3 Molecular differences between HR (basic) and HR (outliers) patients.** A)
 580 Heatmap of 38 differentially expressed proteins. LR, low-risk patients. HR, high-risk
 581 patients. B) Boxplots of 13 selected differentially expressed proteins. C) Proposed
 582 mechanism for serum LDH elevation in COVID-19 patients.



583